ALX Oncology Holdings Inc (ALXO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.01-0.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALXO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress clinical trials of evorpacept and ALX2004 with key data readouts expected in 2026-2027.
Stated as a priority in 3 of last 3 quarters. Management reports ASPEN-09-Breast trial enrollment on track for topline data mid-2027 and ALX2004 Phase 1 safety data expected in second half of 2026. Clinical data presentations in late 2025 and early 2026 validate the development strategy. The trajectory is delivering consistent progress toward clinical milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Enrollment in ASPEN-09-Breast trial remains on track for topline data mid-2027; ALX2004 safety data on track for 2H 2026.”
“Phase 2 ASPEN-09-Breast trial on track for topline data mid-2027; ALX2004 dose-escalation safety data expected in 2H 2026.”
“Data presented from Phase 1b/2 trial of evorpacept plus zanidatamab showed durable responses in HER2-positive patients.”
Ensure financial resources are adequate to support ongoing operations through early 2027 and beyond.
Stated as a priority in 3 of last 3 quarters. Cash, cash equivalents and investments were $169.1 million in 2026-Q1 and $153.4 million in 2026-Q2, supporting management's statement of sufficient funding through at least Q1 2027 and into first half of 2028. The trajectory shows strong financial resources consistent with management's funding guidance.
“Cash, cash equivalents and investments were $153.4 million; sufficient to fund planned operations through first half of 2028.”
“Cash, cash equivalents and investments were $169.1 million; sufficient to fund planned operations through first half of 2028.”
“Company believes cash, cash equivalents and investments are sufficient to fund planned operations into Q1 of 2027.”
Enhance management team and operational infrastructure to support clinical development and corporate growth.
Stated as a priority in 3 of last 3 quarters. Management appointed Jeff Knight as Chief Development and Operating Officer in 2026-Q1 and Scott Garland as Chairman of the Board in 2026-Q2, enhancing leadership and operational capabilities. These appointments align with management's stated focus on strengthening the team to support clinical and corporate milestones, showing delivery on this priority.
“Strengthened leadership with appointments of Scott Garland as Chairman and Michael Listgarten as General Counsel.”
“Appointed Jeff Knight as Chief Development and Operating Officer to strengthen development capabilities and operational infrastructure.”
“Management highlighted strengthening leadership and operational capabilities as a priority.”
Over the trailing year it converted 0.93x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
17 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.